🧬 Amgen Highlights Breakthrough Repatha Data as Heart Attack Risk Falls 20%.
Amgen (AMGN) attracted investor attention after new real-world research showed its cholesterol-lowering drug Repatha reduced heart attack risk by 20% compared with ezetimibe among more than 544,000 adults with cardiovascular disease and previous statin use. The findings, announced November 5, strengthen the commercial case for one of Amgen's key growth products.
The development comes after Repatha generated $1.09 billion in third-quarter sales, increasing 37% year over year. Amgen also reported total Q3 revenue of $10.4 billion, up 8%, and raised its 2026 revenue guidance to $38.9–$39.7 billion. However, declining Prolia sales remain a challenge as patent-related competition intensifies.
For investors, Repatha's expanding clinical evidence could support continued adoption in the competitive cardiovascular drug market. Attention is also turning to Amgen's upcoming November 11 presentation of Phase 3 data for dazodalibep, another potential catalyst for its future growth pipeline.
$AMGN
Amgen (AMGN) attracted investor attention after new real-world research showed its cholesterol-lowering drug Repatha reduced heart attack risk by 20% compared with ezetimibe among more than 544,000 adults with cardiovascular disease and previous statin use. The findings, announced November 5, strengthen the commercial case for one of Amgen's key growth products.
The development comes after Repatha generated $1.09 billion in third-quarter sales, increasing 37% year over year. Amgen also reported total Q3 revenue of $10.4 billion, up 8%, and raised its 2026 revenue guidance to $38.9–$39.7 billion. However, declining Prolia sales remain a challenge as patent-related competition intensifies.
For investors, Repatha's expanding clinical evidence could support continued adoption in the competitive cardiovascular drug market. Attention is also turning to Amgen's upcoming November 11 presentation of Phase 3 data for dazodalibep, another potential catalyst for its future growth pipeline.
$AMGN